{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:27:09Z","timestamp":1793899629199,"version":"4.8.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Military medical innovation project","award":["16CXZ023"],"award-info":[{"award-number":["16CXZ023"]}]},{"name":"Key Science and Technology Program of Shaanxi Province","award":["2014k11\u201103-05-01"],"award-info":[{"award-number":["2014k11\u201103-05-01"]}]},{"name":"Xijing Hospital subject booster plan translational medicine research projects","award":["XJZT13Z05"],"award-info":[{"award-number":["XJZT13Z05"]}],"id":[{"id":"https:\/\/ror.org\/05cqe9350","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.biopha.2019.109001","type":"journal-article","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T23:22:57Z","timestamp":1558826577000},"page":"109001","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Coupling the near-infrared fluorescent dye IR-780 with cabazitaxel makes renal cell carcinoma chemotherapy possible"],"prefix":"10.1016","volume":"116","author":[{"given":"Yu","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangdong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarui","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2019.109001_bib0005","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2019.109001_bib0010","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1056\/NEJMcp0910041","article-title":"Clinical practice. Small renal mass","volume":"362","author":"Gill","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2019.109001_bib0015","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.juro.2012.09.056","article-title":"Optical imaging of kidney cancer with novel near infrared heptamethine carbocyanine fluorescent dyes","volume":"189","author":"Yang","year":"2013","journal-title":"J. Urol."},{"key":"10.1016\/j.biopha.2019.109001_bib0020","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2019.109001_bib0025","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00345-004-0469-x","article-title":"Chemotherapy in metastatic renal cell cancer","volume":"23","author":"Lilleby","year":"2005","journal-title":"World J. Urol."},{"key":"10.1016\/j.biopha.2019.109001_bib0030","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/CAD.0b013e3280a02f17","article-title":"Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy","volume":"18","author":"Petrioli","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.biopha.2019.109001_bib0035","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/COC.0b013e31820dbc17","article-title":"Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma","volume":"35","author":"Tsimafeyeu","year":"2012","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2019.109001_bib0040","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/COC.0b013e3181925176","article-title":"A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: southwest Oncology Group Study S0312","volume":"32","author":"Van Veldhuizen","year":"2009","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2019.109001_bib0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2490-9-6","article-title":"Expression of multidrug resistance markers ABCB1 (MDR-1\/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma","volume":"9","author":"Walsh","year":"2009","journal-title":"BMC Urol."},{"key":"10.1016\/j.biopha.2019.109001_bib0050","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejphar.2011.08.030","article-title":"Impact of cisplatin administration on protein expression levels in renal cell carcinoma: a proteomic analysis","volume":"670","author":"Vasko","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2019.109001_bib0055","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/path.2689","article-title":"VHL and HIF signalling in renal cell carcinogenesis","volume":"221","author":"Baldewijns","year":"2010","journal-title":"J. Pathol."},{"key":"10.1016\/j.biopha.2019.109001_bib0060","doi-asserted-by":"crossref","first-page":"9056","DOI":"10.1158\/0008-5472.CAN-09-1770","article-title":"Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells","volume":"69","author":"Roberts","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2019.109001_bib0065","doi-asserted-by":"crossref","first-page":"401","DOI":"10.4161\/cbt.19291","article-title":"Inhibition of STAT1 sensitizes renal cell carcinoma cells to radiotherapy and chemotherapy","volume":"13","author":"Zhu","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biopha.2019.109001_bib0070","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.eururo.2004.11.013","article-title":"Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma","volume":"47","author":"Kausch","year":"2005","journal-title":"Eur. Urol."},{"key":"10.1016\/j.biopha.2019.109001_bib0075","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0022-5347(01)65915-9","article-title":"Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP),glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney","volume":"156","author":"Kim","year":"1996","journal-title":"J. Urol."},{"key":"10.1016\/j.biopha.2019.109001_bib0080","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/mc.20267","article-title":"Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells","volume":"46","author":"Sato","year":"2007","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.biopha.2019.109001_bib0085","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nprot.2007.30","article-title":"In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro","volume":"2","author":"Liang","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.biopha.2019.109001_bib0090","doi-asserted-by":"crossref","DOI":"10.3791\/51046","article-title":"In vitro cell migration and invasion assays","author":"Justus","year":"2014","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.biopha.2019.109001_bib0095","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1021\/acssensors.7b00551","article-title":"Fluorescent sensors based on aggregation-induced emission: recent advances and perspectives","volume":"2","author":"Gao","year":"2017","journal-title":"ACS Sens."},{"key":"10.1016\/j.biopha.2019.109001_bib0100","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0140-6736(15)00046-X","article-title":"Renal cancer","volume":"387","author":"Capitanio","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2019.109001_bib0105","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2019.109001_bib0110","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.critrevonc.2015.08.007","article-title":"Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy","volume":"96","author":"Diamond","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.biopha.2019.109001_bib0115","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/CAD.0b013e3283609ec1","article-title":"Chemotherapy in metastatic renal cell carcinoma today? A systematic review","volume":"24","author":"Buti","year":"2013","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.biopha.2019.109001_bib0120","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.bbrc.2017.06.115","article-title":"Inhibition of mitochondrial translation effectively sensitizes renal cell carcinoma to chemotherapy","volume":"490","author":"Wang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2019.109001_bib0125","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22195","article-title":"Targeting mitochondria by anthelmintic drug atovaquone sensitizes renal cell carcinoma to chemotherapy and immunotherapy","volume":"32","author":"Chen","year":"2018","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.biopha.2019.109001_bib0130","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1016\/j.biomaterials.2013.05.071","article-title":"IR-780 dye loaded tumor targeting theranostic nanoparticles for NIR imaging and photothermal therapy","volume":"34","author":"Yue","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2019.109001_bib0135","doi-asserted-by":"crossref","first-page":"25968","DOI":"10.1038\/srep25968","article-title":"IR-780 dye as a sonosensitizer for sonodynamic therapy of breast tumor","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2019.109001_bib0140","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041189","article-title":"A lipophilic IR-780 dye-encapsulated zwitterionic polymer-lipid micellar nanoparticle for enhanced photothermal therapy and NIR-Based fluorescence imaging in a cervical tumor mouse model","volume":"19","author":"Rajendrakumar","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2019.109001_bib0145","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1146\/annurev-pharmtox-010510-100556","article-title":"The expression and function of organic anion transporting polypeptides \u202fin normal tissues and in cancer","volume":"52","author":"Obaidat","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2019.109001_bib0150","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/bdd.1915","article-title":"Putative roles of organic anion transporting polypeptides (OATPs) in cell survival and progression of human cancers","volume":"35","author":"Nakanishi","year":"2014","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.biopha.2019.109001_bib0155","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.patbio.2005.03.003","article-title":"Update on tubulin-binding agents","volume":"54","author":"Attard","year":"2006","journal-title":"Pathol Biol (Paris)"},{"key":"10.1016\/j.biopha.2019.109001_bib0160","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.3892\/ijo.2016.3693","article-title":"Synthesis of IR-780 dye-conjugated abiraterone for prostate cancer imaging and therapy","volume":"49","author":"Yi","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2019.109001_bib0165","first-page":"6671","article-title":"Effects of Cabazitaxel in renal cell carcinoma cell lines","volume":"35","author":"Mizutani","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.biopha.2019.109001_bib0170","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1158\/0008-5472.CAN-15-2078","article-title":"Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer","volume":"76","author":"Martin","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2019.109001_bib0175","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1080\/10717544.2019.1588424","article-title":"Application and design of esterase-responsive nanoparticles for cancer therapy","volume":"26","author":"Dong","year":"2019","journal-title":"Drug Deliv."},{"key":"10.1016\/j.biopha.2019.109001_bib0180","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1208\/s12248-015-9740-x","article-title":"Role of organic anion-transporting polypeptides (OATPs) in Cancer therapy","volume":"17","author":"Thakkar","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.biopha.2019.109001_bib0185","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1146\/annurev-pharmtox-010510-100556","article-title":"The expression and function of organic anion transporting polypeptides in normal tissues and in cancer","volume":"52","author":"Obaidat","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332219310662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332219310662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:52:12Z","timestamp":1793897532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332219310662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":37,"alternative-id":["S0753332219310662"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2019.109001","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coupling the near-infrared fluorescent dye IR-780 with cabazitaxel makes renal cell carcinoma chemotherapy possible","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2019.109001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"109001"}}